Quantitative determination of citalopram hydrobromide by spectro-photometry and chemometry in presence of its degradation products and additivesin pharmaceutical preparation
Loading...
Date
2016
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Analytical Chemistry: An Indian Journal
Series Info
ACAIJ;Volume: 16 Issue: 2 Pages: 53-62
Doi
Scientific Journal Rankings
Abstract
Simple, accurate, sensitive and validated UV stability-indicating spectro- photometric and chemometric methods were developed for determination
of Citalopram Hydrobromide (CT) in presence of its alkaline, oxidative degradation products and in its pharmaceutical preparation. Method (A) is a
successive derivative ratio spectrophotometricone, which depends on the
successive derivative ofratio spectra in two steps and measuring Citalopram
Hydrobromide at 277nm and 293nm. Method (B) is mean centering of ratio
spectra which dependson using the mean centered ratio spectra in two
successive steps and measuring the mean centeredvalues of the second
ratio spectra at 237nm and method (C) used two chemometric techniques ;
principal component regression(PCR) and partial least-squares (PLS). The
proposed methods werechecked using laboratory-prepared mixtures and
were successfully applied for the analysis of pharmaceuticalformulation
containing Citalopram Hydrobromide. The proposed methods were vali- dated according to the ICH guidelines. The obtained results were statisti- cally compared with those obtained froma compendial HPLC method,showing no significant difference with respect to accuracy and precision.
Description
MSA Google Scholar
Keywords
University of Citalopram hydrobromide; Degradation; Stability-indicating; Successive derivative ratio; Mean centering of ratio spectra; Chemometrics
Citation
[1] P.Baumann; International Clinical Psychopharma- cology, 11, (1996). [2] J.Menegola, M.Steppe, E.E.S.Schapoval;J.AOAC Int., 91, (2008). [3] J.Macek, P.Ptacek J.Kima; J.Chromatogr.B, 755, (2001). [4] HPLC method supplied by SEDICO company through personal communication. [5] B.Narayana, K.Veena; J.Mex.Chem.Soc., 54, (2010). [6] A.Raza; Chem.Pharm.Bull., 54, (2006). [7] I.A.Darwish, I.H.Refaat; J.AOAC Int., 89, (2006). [8] T.G.Halvorsen, S.Pedersen-Bjergaard, K.E.Rasmussen;J.Chromatogr.A, 909, (2001). [9] Z.Rong, X.Shangyou, X.Hongmei, H.Rui, X.Zhining; Chin.j.Anal.chem., 34, (2006). [10] J.J.B.Nevado, C.G.Cabanillas, M.J.V.Llerena, V.R.Robledo;J.Chromatogr.A, 1072, (2005). [11] S.R.Dhaneshwar, M.V.Mahadik; J.AOAC Int., 92, (2009). [12] R.N.Rao, A.N.Raju, R.Narsimha; J.Sep.Sci., 31, (2008). [13] M.Sharma, P.R.Jawa, R.S.Gill, G.Bansal; J.Braz.Chem.Soc., 22, (2011). [14] A.Afkhami, M.Bahram; Spectrochim Acta A Mol Biomol Spectrosc, 61, (2005). [15] A.Afkhami, M.Bahram; Talanta, 66, (2005). [16] E.DinÁ, ÷.‹st¸ndað; Il Farmaco, 58, (2003). [17] R.G.Brereton;Analyst, 122, (1997). [18] H.W.Darwish, S.A.Hassan, M.Y.Salem, B.A.El- Zeiny; SpectrochimActaAMol Biomol Spectrosc, 83, (2011). [19] ICHóInternational Conference on Harmonization, of Technical Requirementsfor registration of Phar- maceuticalsfor Human Use Topic Q2 (R1), Validation of Analytical Procedures; Text and Methodol- ogy, Geneva, Switzerland, (2005). [20] R.Kramer; Chemometric Techniques for Quantitative analysis, Marcel dekker; New York, (1998). [21] F.Navarro-Villosalade,L.V.Prez-Arrbas, M.E.Leon- Gonzalez, L.M.Polo-Diez; Anal.Chim.Acta, 313, (1995). [22] K.R.Beebe,R.J.Pell, M.B.Seashlotz;Chemometrics, APractical Guide,JohnWiley, Sons,Inc., NewYork, (1998).